Genevieve Neal-Perry, MD, PhD, sits down with Contemporary OB/GYN to discuss positive data from a recent phase 3 study evaluating fezolinetant (Astellas) for vasomotor symptoms (VMS).
S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
March 2nd 2022In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Listen
First patient dosed in RECONNECT trial of RE104 for postpartum depression
July 23rd 2024Reunion Neuroscience Inc. initiates phase 2 trial of RE104, a novel short-duration psychedelic treatment for postpartum depression, aiming to provide rapid and effective relief for affected mothers.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
FDA grants fast track to 99mTc-maraciclatide for endometriosis diagnosis
Published: July 2nd 2024 | Updated: July 2nd 2024Serac Healthcare’s 99mTc-maraciclatide, a new radio-labelled tracer, gains FDA Fast Track Designation for its potential to improve non-invasive diagnosis of superficial peritoneal endometriosis in patients aged 16 and older.
Read More
Study finds estrogen therapy underuse after oophorectomy raises health risks
June 19th 2024A recent highlights elevated morbidity and mortality risks in premenopausal women underusing estrogen therapy after oophorectomy, underscoring the critical need for hormone therapy to mitigate adverse health outcomes.
Read More